Prices delayed by at least 15 minutes | Print
Cellectis SA (CLLS)
American Depository ReceiptThis share can be held in a Dealing accountSIPP
Company profile
Cellectis SA is a biotechnology company focused on developing immunotherapies for cancer. The company engages in gene editing in an attempt to lead the body's immune system toward attacking cancer cells. Cellectis utilizes strategic corporate partnerships along with cooperation through various university clinical centers. The company's gene-editing technologies allow for the creation of healthy cells derived from healthy donors rather than the patients themselves. It reportstwo segments: Therapeutics and Plants. Its Therapeutics segment focuses on novel cancer therapies, while its Plants segment focuses on agricultural biotechnology.
Address
8 rue de la Croix Jarry
Paris
FRA
75013
Forecast key dates
Name | Key Date |
---|---|
Cellectis SA Annual Report for 2024 | 2025-04-29T00:00:00 |
Cellectis SA Third Quarter Earnings Conference Call for 2024 | 2024-11-07T08:00:00 |
Cellectis SA Third Quarter Earnings Results for 2024 | 2024-11-06T00:00:00 |
Cellectis SA Second Quarter Earnings Conference Call for 2024 | 2024-08-02T08:00:00 |
Cellectis SA Second Quarter Earnings Results for 2024 | 2024-08-02T00:00:00 |
Cellectis SA Annual General Meeting for 2023 | 2024-06-27T00:00:00 |
Cellectis SA Fourth Quarter Earnings Result for 2023 | 2024-05-07T00:00:00 |
Cellectis SA Fourth Quarter Earnings Conference Call for 2023 | 2024-05-07T00:00:00 |
Cellectis SA First Quarter Earnings Conference Call for 2024 | 2024-05-03T08:00:00 |
Cellectis SA First Quarter Earnings Results for 2024 | 2024-05-03T00:00:00 |
Previous key dates
Name | Key Date |
---|---|
Cellectis SA Fourth Quarter Earnings Result for 2023 | 2024-05-07T00:00:00 |
Cellectis SA Fourth Quarter Earnings Conference Call for 2023 | 2024-05-07T00:00:00 |
Cellectis SA First Quarter Earnings Conference Call for 2024 | 2024-05-03T08:00:00 |
Cellectis SA First Quarter Earnings Results for 2024 | 2024-05-03T00:00:00 |
Cellectis SA Annual Report for 2023 | 2024-04-29T00:00:00 |
Cellectis SA Third Quarter Earnings Conference Call for 2023 | 2023-11-07T08:00:00 |
Cellectis SA Third Quarter Earnings Results for 2023 | 2023-11-06T00:00:00 |
Cellectis SA Second Quarter Earnings Conference Call for 2023 | 2023-08-04T08:00:00 |
Cellectis SA Second Quarter Earnings Results for 2023 | 2023-08-03T00:00:00 |
Cellectis SA Annual General Meeting for 2022 | 2023-06-27T14:30:00 |
Cellectis SA First Quarter Earnings Conference Call for 2023 | 2023-05-05T08:00:00 |
Cellectis SA First Quarter Earnings Results for 2023 | 2023-05-04T00:00:00 |
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2024 AJ Bell. All rights reserved.